Register of Telaprevir and Boceprevir in Routine Clinical Practice

Fundación Pública Andaluza Progreso y Salud

Status: Completed

Conditions: Hepatitis C

Study type: Observational

Funder types: Other

Identifiers

NCT02004379

FPS-TEL-2013-01

Details and patient eligibility

About

Know through routine clinical practice the effectiveness and safety of current treatment of hepatitis C virus, genotype 1, for patients who have never been treated and for patients who have been previously treated

Enrollment: 1,553 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients infected by hepatitis C virus, genotype 1
• Indication of treatment with telaprevir or boceprevir in F3 and F4 fibrosis

Exclusion criteria

• Being taking part in other
• Inability to follow a monitoring
• Contra-indications on triple therapy
• Coinfected with HIV and HBV (hepatitis B virus)

Trial design

1,553 participants in 1 patient group

Patients with hepatitis C, genotype 1

Description:

Patients with hepatitis C, genotype 1, treated with telaprevir or boceprevir